Dambkowski Carl 4

What Happened

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), sold 26,400 shares on June 22, 2026.
• The shares were disposed at a weighted average price of $132.60 per share, for total proceeds of $3,500,640. This transaction is reported as a sale (disposition), which is often routine rather than a direct signal about the company.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (timely filing).
• Price: weighted average $132.60; individual sale prices ranged from $132.550 to $132.645. The reporting person can provide a breakdown of quantities at each price on request.
• Shares sold: 26,400; Total proceeds: $3,500,640.
• Footnote: The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• Shares owned after transaction: not specified in the materials you provided.

Context

• The filing indicates an open-market/private sale under a pre-established 10b5-1 plan. 10b5-1 plans allow insiders to sell shares according to a set schedule and are commonly used to avoid questions about timing.
• As with all insider sales, this is a factual disclosure of a transaction; it does not, by itself, prove management sentiment about the company.